首页> 外文OA文献 >Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

【2h】

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

机译：Secukinumab优于富马酸酯，治疗患有中度至严重的斑块牛皮癣患者，尚无严重的牙龈，尚无危险的系统治疗方法：随机受控原料试验结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M. Sticherling; U. Mrowietz; M. Augustin; D. Thaçi; N. Melzer; C. Hentschke; J. Kneidl; C. Sieder; K. Reich;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial [J] . Sticherling M., Mrowietz U., Augustin M., British Journal of Dermatology . 2017,第4期

机译：Secukinumab优于富马酸酯，治疗患有中度至严重的斑块牛皮癣患者，他是天真的全身治疗方法：随机受控原始试验结果
2. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial (vol 177, pg 1024, 2017) [J] . Sticherling M., Mrowietz U., Augustin M., British Journal of Dermatology . 2017,第6期

机译：Secukinumab优于富马酸酯，治疗患有中度至严重的斑块牛皮癣的患者，他是天真的全身治疗方法：随机受控原始试验（Vol 177，PG 1024,2017）的结果
3. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS) [J] . Thaci D., Pinter A., Sebastian M., British Journal of Dermatology . 2020,第2期

机译：Guselkumab在患有中度至严重的斑块牛皮癣的患者中优于富马酸酯，该蛋白质是全身治疗的天真：来自随机的活性比较器控制的阶段试验（Polaris）的结果
4. Controlled delivery of fumaric acid - a new possibility in the treatment of psoriasis [C] . O. Malka, J. Kost, N. Grossman International symposium on controlled release of bioactive materials;Consumer and diversified products conference . 1998

机译：富马酸的控制输送-银屑病治疗的新可能性
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Short-Term Efficacy and Safety of IL-17 IL-12/23 and IL-23 Inhibitors Brodalumab Secukinumab Ixekizumab Ustekinumab Guselkumab Tildrakizumab and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [O] . Fan Bai, Gang Gang Li, Qingmin Liu, 2019

机译：IL-17IL-12 / 23和IL-23抑制剂BrodalumabSecukinumabIxekizumabUstekinumabGuselkumabTildrakizumab和Risankizumab治疗中度至重度斑块状牛皮癣的短期疗效和安全性：系统评价和随机对照试验的网络元分析
7. Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS) [O] . D. Thaçi, A. Pinter, M. Sebastian, 2020

机译：Guselkumab在患者中优于富马酸酯，患者中度至严重的斑块牛皮癣是天真的系统性治疗：随机，活性比较器控制阶段试验（Polaris）的结果

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial

著录项

引文网络

相似文献

相关主题

期刊订阅